<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00434941</url>
  </required_header>
  <id_info>
    <org_study_id>GEICAM/2005-01</org_study_id>
    <nct_id>NCT00434941</nct_id>
  </id_info>
  <brief_title>Capecitabine Plus Radiotherapy for Local Relapse Breast Cancer With Negative Her2 Tumours</brief_title>
  <official_title>Multicenter Phase IV.II Trial, for the Administration of Capecitabine Simultaneous to Radiotherapy for Local Relapse Breast Cancer Patients With Negative Her2 Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Breast Cancer Research Group</source>
  <brief_summary>
    <textblock>
      This is a prospective, open-label, multicenter phase IV.II study. Patients with local relapse
      breast cancer will receive radiotherapy concomitant to the administration of capecitabine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total dose of radiotherapy will be 50 Gy administered in daily session of 200 centigray
      (cGy). Radiotherapy treatment will not be longer than 6 weeks.

      All patients will receive 1650 mg/m2 by mouth, per day (825 mg/m2 twice a day (p.o. bid) for
      35 days.

      Tissue samples must be analysed to determinate the human epidermal growth factor receptor-2
      (HER2) by fluorescent in situ hybridization (FISH) technical.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to the slow rate of recruitment the study was stopped.
  </why_stopped>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete clinical response rate</measure>
    <time_frame>28 days after the end of the radiotherapy</time_frame>
    <description>The disease evaluation will be measured by RECIST criteria in the 28 days after the end of the radiotherapy by Magnetic resonance imaging (MRI).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the concomitant administration of capecitabine and radiotherapy as the first treatment</measure>
    <time_frame>28 days after the end of the radiotherapy</time_frame>
    <description>Safety will be assessed by standard clinical and laboratory tests. Adverse events grade will be defined by the National Cancer Institute Common Terminology Criteria for Adverse (NCI-CTCAE).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Radiotherapy + Capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy (for 25 days; Dose: 50 Gy) + Capecitabine (for 35 days; Dose: 825 mg/m2 twice per day p.o.) Experimental treatment consists of administration of 825 mg/m2 x 2 daily p.o., for 7 days simultaneously with daily radiotherapy treatment.Capecitabine will be administered for 35 days as maximum.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <arm_group_label>Radiotherapy + Capecitabine</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <arm_group_label>Radiotherapy + Capecitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent.

          -  Histological diagnoses of operable invasive adenocarcinoma of the breast.

          -  Patients with tumour HER2 negative.

          -  Previous mastectomy surgery.

          -  Actual diagnoses of local recurrence of breast cancer.

          -  Patients must not present evidence of metastatic disease.

          -  Age &gt;= 18 years old.

          -  Performance status (Karnofsky index) &gt;= 70.

          -  Laboratory results (within 14 days prior to randomization):

          -  Hematology:

               -  neutrophils &gt;= 1.5 x 10e9/l;

               -  platelets &gt;= 100x 10e9/l;

               -  hemoglobin &gt;= 10 mg/dl

          -  Hepatic function:

               -  total bilirubin &lt;= 1,5 upper normal limit (UNL);

               -  Alanine transaminase (SGOT) and aspartate aminotransferase (SGPT) &lt;= 1.5 UNL;

               -  alkaline phosphatase &lt;= 1.5 UNL.

          -  Renal Function:

               -  creatinine &lt;= 175 µmol/l (2 mg/dl)or creatinine clearance &gt;= 60 ml/min.

        Exclusion Criteria:

          -  Distant metastasis or metastatic disease in organs.

          -  Metastasis in internal mammary chain lymph nodes

          -  Previous radiation treatment on the breast or other locations (30% or greater of the
             bone marrow).

          -  Prior treatment with continuous (greater than 24h) 5-fluorouracil (5-FU) infusion,
             capecitabine or other oral fluoropyrimidines such as eniluracil/5-FU , uracil/tegafur,
             S1 or emitefur.

          -  Known hypersensitivity to capecitabine, doxifluridine or any of its components.

          -  Organ allografts that require an immunosuppressor therapy.

          -  History of neurological or psychiatric disorders, which could preclude the patients to
             free informed consent.

          -  Clinically significant cardiac disease such as congestive heart failure, symptomatic
             coronary artery disease and cardiac arrhythmia not well controlled with medication or
             history of myocardial infarction within the last 12 months or uncontrolled
             hypertension.

          -  Evidence of central nervous system (CNS) metastases. Pts with a history of
             uncontrolled seizures, CNS disorders or psychiatric disability judged by the
             investigator to be clinically significant precluding informed consent or interfering
             with compliance should be excluded from the study.

          -  Pregnant or lactating women. Adequate contraceptive methods must be used during
             chemotherapy and hormone therapy treatments. Negative pregnancy test in the 14
             previous days to randomization.

          -  Active uncontrolled infection or other severe pathologies such as active peptic ulcer,
             unstable diabetes mellitus.

          -  Major surgery during 4 weeks prior to treatment.

          -  Patients lacking physical integrity of upper gastrointestinal tract or with history of
             bad absorption syndrome.

          -  Anticoagulant treatment with coumadin anticoagulants.

          -  Concomitant treatment with other investigational products. Participation in other
             clinical trials with a non-marketed drug in the 30 previous days before randomization.

          -  Concomitant treatment with other therapy for cancer.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Clínico Universitario San Carlos</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Infanta Cristina</name>
      <address>
        <city>Badajoz</city>
        <zip>06080</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Esperanza</name>
      <address>
        <city>Barcelona</city>
        <zip>08024</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.geicam.org</url>
    <description>Sponsor's website</description>
  </link>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 13, 2007</study_first_submitted>
  <study_first_submitted_qc>February 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2007</study_first_posted>
  <last_update_submitted>February 19, 2019</last_update_submitted>
  <last_update_submitted_qc>February 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Administration of capecitabine concomitant to radiotherapy</keyword>
  <keyword>Her2: negative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

